Psomagen, Inc. (South Korea)

The company is an integrative omics solutions and contract laboratory services provider. The Company's labs are United States-based and are Clinical Laboratory Improvement Amendments (CLIA) certified and include certified authorization professional (CAP) accredited facilities. Its omics services include Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Sanger Sequencing, Microarray Analysis, Epigenomics Sequencing, Metagenomics Sequencing, Ribonucleic acid (RNA) Sequencing, Single-Cell Sequencing and Biomarker Profiling. It also offers SARS-CoV-2 Variant Sequencing services. The Microarray Analysis is a multiplex genomics approach that targets and quantifies specific genes by hybridizing the nucleic acid to a chip and providing an output of genotyping data on a genome-wide scale. Epigenomics is the study of epigenetic changes, such as chromatin assembly, histone modification, and Deoxyribonucleic acid DNA-protein interaction in a cell. The Company was established on December 2, 2004. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 13, 2020.